GM-K562 cell vaccine

BIOLOGICAL2 trials

Sponsors

Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

Leukemia

Phase 1

Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

CompletedNCT00301093

Dana-Farber Cancer InstituteLeukemia

Start: 2005-09-30End: 2020-09-10Updated: 2020-10-28

Phase 2

Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI

CompletedNCT00363649

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLeukemia

Start: 2006-09-30End: 2017-09-30Updated: 2018-11-13